𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Choosing the optimal endpoint(s) for a clinical trial on transfusion

✍ Scribed by Jean-François Hardy; Richard B. Weiskopf

Book ID
110744181
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
34 KB
Volume
45
Category
Article
ISSN
0372-1248

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Screening for ovarian cancer: What are t
Screening for ovarian cancer: What are the optimal surrogate endpoints for clinical trials?
✍ Beth Y. Karlan 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 634 KB

The inability to identify relevant markers for presymptomatic screening in early stage or "preinvasive" ovarian cancer has plagued investigators and clinicians facing the problems of early detection. The characteristic late stage of disease at initial presentation has hindered our understanding of t

Controlling alpha in a clinical trial: t
Controlling alpha in a clinical trial: the case for secondary endpoints
✍ Ralph B. D'Agostino Sr 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

We have become masters of clinical trials. We design them beautifully, our protocols delineate objectives and categorize sharply e$cacy variables as primary or secondary, teams of investigators execute them e$ciently and then we analyse with the latest and most sophisticated statistical methods. Yet

A rationale for expanding the endpoints
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma
✍ Mace L. Rothenberg; James L. Abbruzzese; Malcolm Moore; Russell K. Portenoy; Joh 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 689 KB

## BACKGROUND. Using classical endpoints, such as response rate and survival, as the sole measures of benefit, little progress has been made in the treatment of advanced pancreatic carcinoma in the past 30 years. We challenge the assumption that response rate and survival are the only appropriate